Market research
6869.TSE Sysmex Corporation
TSE JPY Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 1T
- P/E ratio
- 29.09
- Analyst target
- 2121.4285
- Dividend yield
- 1.9%
- Beta
- 0.77
Profile
Company facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- JP3351100007
- Market cap
- 1T
- P/E ratio
- 29.09
- Analyst target
- 2121.4285
- Dividend yield
- 1.9%
- Beta
- 0.77
About
About Sysmex Corporation
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers hematology, a major test routinely included in blood tests; Flow Cytometry (FCM) analyzes cell properties by irradiating individual cells with a laser and measuring the intensity of light scattering and fluorescence; urinalysis test checks for the presence of glucose, proteins, and blood in urine; clinical chemistry; hemostasis; immunochemistry; cancer gene testing; and antimicrobial susceptibility testing. The company also provides Caresphere, an ICT solution, which integrates and analyzes real time various data managed through testing instruments and clinical testing information systems, and supports the efficient operation of clinical laboratories; and involved in the medical robotics business. It serves products and services to medical institutions, clinical laboratories, animal hospitals, and research institutes. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 6869.TSE discussion.
5 years, 6 months ago
Sysmex Corporation is currently in a long term uptrend where the price is trading 14.3% above its 200 day moving average.
From a valuation standpoint, the stock is 88.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.4.
Sysmex Corporation's total revenue rose by 6.1% to $80B since the same quarter in the previous year.
Its net income has increased by 18.9% to $11B since the same quarter in the previous year.
Finally, its free cash flow grew by 554.6% to $13B since the same quarter in the previous year.
Based on the above factors, Sysmex Corporation gets an overall score of 5/5.